Meet Jason Mouabbi, M.D.
Present Title & Affiliation
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Hormone receptor positive (HR+) metastatic breast cancer
Invasive lobular carcinoma (ILC)
Education & Training
|2014||St George's University, True Blue, GRN, MD, Doctor of Medicine|
|2010||Wayne State University, Detroit, MI, USA, MS, Master in Biotechnology|
|2009||Wayne State University, Detroit, MI, USA, BS, Bachelor of Science in Biological Science|
|2020-2021||Clinical Instructorship, Breast Cancer, Baylor College of Medicine, Houston, TX|
|2017-2020||Clinical Fellowship, Hematology/oncology, Ascension St. John Hospital, Detroit, MI|
|2014-2017||Clinical Residency, Internal Medicine, Ascension St. John Hospital, Detroit, MI|
|2012-2014||Student Rotation, Ascension St. John Hospital, Detroit, MI|
|2020||American Board of Internal Medicine Hematology|
|2020||American Board of Internal Medicine Medical Oncology|
|2017||American Board of Internal Medicine|
Experience & Service
Assistant Professor, Department of Hematology/Medical Oncology, Division of Internal Medicine, The University of Texas Medical Branch, League City, TX, 2021 - Present
Instructor, Department of Breast Medical Oncology, Division of Cancer Medicine, Baylor College of Medicine, Houston, TX, 2020 - 2021
Scientific Advisory Board Member, Lobular Breast Cancer Alliance, Boston, MA, 2022 - Present
Institutional Committee Activities
Member, Advanced Breast Cancer Steering Committee, 2022 - Present
Committee Member, Academic Review Committee, 2022 - Present
Member, Translational Breast Cancer Research Consortium, Estrogen Receptor Working Group, 2021 - Present
Member, Hormone-Receptor Positive Breast Cancer Clinical Trial Working Group, 2021 - Present
Honors & Awards
|2022||GRASP Award, Guiding Researchers and Advocates to Scientific Partnerships|
|2022||Breast Cancer Research Foundation Scholarship, The Breast Cancer Research Foundation|
|2021||Lester & Sue Smith Breast Cancer Award of Excellence, Baylor College of Medicine, Dan L. Duncan Comprehensive Cancer Center|
|2021||Honorary Onco-Hospitalist, The University of Texas MD Anderson Cancer Center|
|2020||Hematology/Oncology Chief Fellow, Ascension St. John Hospital|
|2019||Top Doctor Award, Detroit Hour Magazine|
|2017||Resident Research Day Winner, Ascension St John Hospital|
|2017||Excellence in Research, Southeast Michigan Center for Medical Education|
|2017||Resident of the Year, Ascension St John Hospital|
|2017||Excellence in Research, Ascension St John Hospital|
|2017||Original Research Oral Section 1st place winner, American College of Physicians|
|2017||Young Investigator Award, Asian Pacific Society of Respirology|
|2017||Young Investigator Award, American College of Chest Physicians|
|2015||Regional Meeting Clinical Vignette Winner, American College of Physician Michigan Chapter|
|2015||Intern of the year, Ascension St John Hospital|
|2010||Geoffrey H. Bourne Scholarship Recipient, St. Georges University|
|2007||Downy Scholarship Recipient, Wayne State University|
|2007||Outstanding Performance, Wayne State University|
|2006||Top 10% Graduate, Wayne State University|
- Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer 191:113250, 2023. e-Pub 2023. PMID: 37573674.
- Mouabbi JA, Singareeka Raghavendra A, Bassett RL, Hassan A, Tripathy D, Layman RM. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open 6(5):e2313017, 2023. e-Pub 2023. PMID: 37166793.
- Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, Dehdashti F, Kurland BF, Mortimer J, Mouabbi J, Moon DH, de Vries EGE. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol. J Nucl Med 64(3):351-354, 2023. PMID: 36863779.
- Mouabbi JA, Raghavendra AS, Bassett RL, Hassan A, Tripathy D, Layman RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. NPJ Breast Cancer 8(1):131, 2022. e-Pub 2022. PMID: 36539444.
- Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 193(2):253-264, 2022. e-Pub 2022. PMID: 35347549.
- Mouabbi JA, Osborne CK, Schiff R, Rimawi MF. Management of hormone receptor-positive human epidermal growth factor 2-negative metastatic breast cancer. Breast Cancer Res Treat 190(2):189-201, 2021. e-Pub 2021. PMID: 34515904.
- Mouabbi JA, Chand M, Asghar IA, Sakhi R, Ockner D, Dul CL, Hadid T, Aref A, Rimawi MF, Hoyos V. Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. Cancer Med 10(14):4790-4795, 2021. e-Pub 2021. PMID: 34080777.
- Moabbi AM, Agarwal N, El Kaderi B, Ansari A. Role for gene looping in intron-mediated enhancement of transcription. Proc Natl Acad Sci U S A 109(22):8505-10, 2012. e-Pub 2012. PMID: 22586116.
Manuals, Teaching Aids, Other Teaching Publications
- Mouabbi, J., Szpunar, S., Saravolatz, L., Kafri, Z., Hadid T.. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Predictive Markers for DVT, 2017.
- Mouabbi J.A., Hadid T.H., UH E. Effectiveness of low-dose CT scan for lung cancer screening in the community setting, 2019.
- Jason A Mouabbi, Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Aida Hassan, Debu Tripathy, Rachel M. Layman. Survival outcomes in metastatic HR-positive, HER2-negative invasive ductal carcinoma compared to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor. Journal of Clinical Oncology 40(16_suppl):1067-1067, 2022. e-Pub 2022.
- Mouabbi J.A., Sako Z., Adballa A., Hadid T., Rimawi M.F.. Peri-operative diagnostic accuracy of magnetic resonance imaging and ultrasonography in breast cancer: A meta-analysis, 2021.
- Mouabbi J.A., Rimawi M.F., Aref A. et al. Radiation therapy improves survival in early stage HER2-positive breast cancer with high-level of tumor infiltrating lymphocytes, 2021.
- Malapati S.J., Mouabbi J.A., Singh S.R.K., Kumar R., et al.. Bilateral masectomy in ductal carcinoma in situ: 10-year analysis of national inpatient sample database, 2020.
- Mouabbi J.A., Chand M., Sakhi R., et al. Improvement of survival with radiation therapy in early stage triple negative breast cancer patients with high level of tumor infiltrating lymphocytes, 2020.
- Mouabbi J, Kafri Z.. 13. In: Management of Anemia: A Comprehensive Guide for Clinicians. 1. Springer: New York, New York, 219-236, 2018.